Journal Article Summary
The article investigates the impact of treatment discontinuation on weight loss and glycemic control in patients with obesity who were treated with semaglutide or tirzepatide. This topic is significant because obesity is a prevalent condition that can lead to serious health issues, including type 2 diabetes. Understanding how discontinuation of these medications affects weight management and blood sugar levels can help improve treatment strategies and patient outcomes in real-world settings.
The study analyzed data from 7,881 adults who began treatment with either semaglutide or tirzepatide between 2021 and 2023. It found that the average weight loss after one year was 8.7%, with those who did not discontinue treatment losing an average of 11.9%. In contrast, patients who discontinued treatment early lost only 3.6%, while those who discontinued later lost 6.8%. Additionally, among patients with prediabetes, those who continued treatment had a greater reduction in glycated hemoglobin levels compared to those who discontinued.
However, the study has limitations, including its focus on a specific population from Ohio and Florida, which may not represent the broader U.S. population. Factors such as temporary medication shortages and the influence of lifestyle changes were not fully accounted for, which could affect the results. Patients should discuss their treatment plans and any concerns about medication discontinuation with their healthcare providers to ensure they receive the most effective care for their obesity and related health issues.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Gasoyan Hamlet, Butsch W. Scott, Schulte Rebecca, Casacchia Nicholas J., Le Phuc, Boyer Christopher B., Griebeler Marcio L., Burguera Bartolome, et al.. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity (Silver Spring, Md.) 2025. DOI: 10.1002/oby.24331. PMID: 40491239. PMCID: PMC12381620.
Featured Pill Pals Product
Tirzepatide --- 72 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Tirzepatide — 72 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
